FIG. 2.
Application of either of two ISS-containing oligonucleotides but not non-ISS control oligonucleotides 2 h after lethal HSV-2 challenge significantly reduced and delayed the incidence (A) and progression (B) of herpetic disease and increased survival (C). Mice, treated intravaginally and topically with either 1018 ISS (•) or C106 ISS (▴), were protected against hair loss and erythema (A) and chronic urine release (B) compared to mice treated with the 1019 non-ISS (○) or 1040 non-ISS (▵) control oligonucleotides. As controls, mice were treated with PBS (⋄) or were not treated (□). As a control for intervention, a 21-dose course of acyclovir (♦) was provided to a final group of mice.